Company profile
Collegium Pharmaceutical, Inc.
NASDAQ: COLL · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ Stoughton, MACIK 0001267565Reports USD
#177 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
73BFH 81DQ 64GM 68SS 70
v0.1 · 65/100 weight · provisional
↑ operating margin, Piotroski F · ↓ growth stability, balance-sheet leverage
Methodology →Revenue TTM
$796.3M
Rev growth YoY (TTM)
+19.9%
Net income (FY)
$62.9M
Employees
423
as of 2026-08-10
Market cap
$955.8M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$780.6M$780.6M2025
Net income$62.9M$62.9M2025
Operating income$179.6M$179.6M2025
Total assets$1.7B$1.7B2025
Liabilities$1.4B$1.4B2025
Equity$301.7M$301.7M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY24
FY25
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Belbuca36%
Xtampza ER32%
Nucynta IR19%
Nucynta ER13%
By geography
Not disclosed.
The read
What is Collegium Pharmaceutical, Inc.’s revenue?
Collegium Pharmaceutical, Inc. booked $780.6M in FY2025 revenue, growing 273% year over year — faster than 91% of Healthcare companies we track, at a 8.1% net margin.
Peers · Healthcare
Caris Life Sciences, Inc.61CGoodRx Holdings, Inc.68BU.S. Physical Therapy, Inc.80B+Alphatec Holdings, Inc.77B+Corcept Therapeutics Incorporated84B+iRhythm Technologies, Inc.75B+Key facts
CEOVikram Karnani
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersStoughton, MA
ExchangeNASDAQ: COLL
Employees423
IPO date2015-05-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.